Core Insights - Eupraxia Pharmaceuticals Inc. announced positive clinical data from its RESOLVE Phase 1b/2a trial for EP-104GI, a treatment for eosinophilic esophagitis (EoE) [2][4] Group 1: Clinical Trial Results - In the fifth cohort of the RESOLVE trial, one patient achieved complete histological remission at 12 weeks, with a significant reduction in eosinophils [3] - All six evaluable patients in the fourth and fifth cohorts reported improved symptoms, with a 41% mean reduction in the Straumann Dysphagia Index (SDI) scores at 12 weeks [3][4] - The fourth cohort showed the largest average reduction in SDI scores to date, with a four-point reduction at 24 weeks [6] - The fifth cohort demonstrated the greatest percentage change in histology scores, with a peak reduction of 100% in Stage and Grade scores and a mean 54% reduction in Composite Stage and Grade scores [3][4] Group 2: Safety and Efficacy - No serious adverse events have been reported across all five cohorts, indicating a favorable safety profile for EP-104GI [3][4] - Plasma fluticasone levels remained predictable and well below those seen in daily fluticasone asthma treatments, with no adverse events such as candidiasis or adrenal suppression reported [4] - The trial is designed as a multicenter, open-label, dose-escalation study, assessing safety, tolerability, pharmacokinetics, and efficacy of EP-104GI [4][10] Group 3: Future Developments - Cohort 6 is fully enrolled and dosed, with 12-week data expected in Q1 2025 [3] - The company plans to periodically disclose additional data from the RESOLVE trial [5]

Exhibit 99.1 EUPRAXIA PHARMACEUTICALS INC. CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months ended September 30, 2024 (Unaudited and Expressed in U.S. Dollars) EUPRAXIA PHARMACEUTICALS INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited and Expressed in U.S. Dollars) CONTENTS | CONSOLIDATED BALANCE SHEETS | 2 | | --- | --- | | CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | 3 | | CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) | 4-5 | | CONSOL ...

Core Insights - Eupraxia Pharmaceuticals Inc. reported its financial results for Q3 2024, highlighting advancements in clinical trials and financial activities [1][2] Clinical Developments - The company advanced its Phase 1b/2a RESOLVE trial for EP-104GI, showing positive results for eosinophilic esophagitis and presenting data at international medical conferences [2][3] - The Phase 2b SPRINGBOARD trial data for EP-104IAR in knee osteoarthritis was published in The Lancet Rheumatology, indicating significant clinical progress [2][3] Financial Performance - Eupraxia incurred a net loss of $6.0 million for Q3 2024, an increase from $4.9 million in Q3 2023, primarily due to reduced other income from changes in financial instruments [4] - Cash reserves decreased to $8.7 million as of September 30, 2024, down from $19.3 million at the end of Q4 2023, with funds allocated for clinical trials and general corporate purposes [5] Funding and Future Outlook - The company raised C$44.5 million through a non-brokered private placement, which, along with existing cash reserves, is expected to fund operations through Q3 2026 [6] - As of September 30, 2024, the company had 35,622,553 common shares outstanding [6] Management Changes - The company strengthened its management team by appointing Dr. Amanda Malone as Chief Operating and Scientific Officer and Dr. Rahul Sarugaser as Executive Vice President of Corporate Development [3]

Exhibit 99.1 EUPRAXIA PHARMACEUTICALS INC. CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months ended June 30, 2024 (Unaudited and Expressed in U.S. Dollars) EUPRAXIA PHARMACEUTICALS INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 (Unaudited and Expressed in U.S. Dollars) | | Three months | | Three months | | Six months | | Six months | | --- | --- | --- | --- | --- | --- | --- | --- | | | ended June 30, | | ended June 30, | | ended June 30, | | ended June 30, | | | 2024 | | 2023 | | ...

Exhibit 99.1 Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results Victoria, B.C. - April 1, 2024 - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results (prepared in accordance with U.S. GAAP) and operational highlights for the fourth quarter ended December 31, 2023. All ...